Endo International plc (NASDAQ: ENDP), a specialty pharmaceutical company, has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp (NASDAQ: BSTC), a commercial-stage biopharmaceutical company, it was reported on Monday.
The deal is valued at USD88.50 in cash per share or an estimated enterprise value of around USD540m (net of approximately USD120 million in cash acquired) at the expected time of deal closure.
Endo has had a strategic relationship with BioSpecifics since 2004, under which BioSpecifics has received a royalty stream from Endo regarding Endo's collagenase-based therapies that include XIAFLEX, marketed by Endo Pharmaceuticals, intended for the treatment of Dupuytren's contracture and Peyronie's disease, and Qwo, the first FDA-approved injectable treatment for cellulite, which is likely to be introduced by Endo Aesthetics in Spring 2021.
The transaction is expected to close in late 2020 and Endo expects to fund the transaction with cash on hand. The deal has been unanimously approved by the boards of directors of both firms.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT